Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Melanoma

Trial Name: Name of Trial: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma.

Protocol ID: E3612

Eligibility:

  • Age 18 years of age and older
  • Untreated or previously received one treatment for measurable unresectable Stage III or Stage IV melanoma.  This does not include any therapies given in the adjuvant setting.
  • Women must not be pregnant or breast-feeding due to the unknown effects on the fetus or infant.
  • Must meet required laboratory values
  • No infection with HIV
  • No active infection with Hepatitis B
  • No active or chronic infection with Hepatitis C
  • Patients are ineligible if they have any history of central nervous system (CNS) metastases.
  • Patients are ineligible if they have a history of any other malignancy from which the patient has been disease-free for less than 2 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix.
  • Patients are ineligible if they have an active infection
  • Patients are ineligible if they have a history of prior treatment with ipilimumab, bevacizumab, or prior CD137 agonist or CTLA-4 inhibitor or agonist.
  • Patients are excluded if they have any prior history of hypertensive crisis or hypertensive encephalopathy.
  • Patients are excluded if they have known involvement of melanoma within the gastrointestinal tract.
  • Patients must not have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
  • Women of childbearing potential and sexually active males must agree to practice abstinence or use an accepted and effective method of contraception.
  • Patients are excluded if they have a non- healing wound or ulcer

Patients are excluded if they have known significant vascular disease (e.g., aortic aneurysm, aortic dissection).

Enrollment: 168 will be enrolled

Benefits:

It is not possible to know at this time if the study drug(s)/study approach is better than the usual care for this cancer, so this study may or may not help you.  But, this study will help researchers learn things that will help people in the future.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Feb 24, 2014

Updated: Oct 16, 2014

« Return to Trials